ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.960
-0.160 (-7.55%)
At close: Dec 20, 2024, 4:00 PM
2.050
+0.090 (4.59%)
After-hours: Dec 20, 2024, 7:03 PM EST
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 308.16% from the current stock price of 1.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADCT stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 3 | 2 | 2 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +410.20% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $6 | Buy | Initiates | $6 | +206.12% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +308.16% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +308.16% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
74.14M
from 69.56M
Increased by 6.58%
Revenue Next Year
82.87M
from 74.14M
Increased by 11.78%
EPS This Year
-1.74
from -2.94
EPS Next Year
-1.62
from -1.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 77.5M | 91.4M | 146.8M | |||
| Avg | 74.1M | 82.9M | 115.1M | |||
| Low | 70.4M | 74.9M | 80.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.4% | 23.2% | 77.1% | |||
| Avg | 6.6% | 11.8% | 38.9% | |||
| Low | 1.2% | 1.0% | -3.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.48 | -1.20 | -0.89 |
| Avg | -1.74 | -1.62 | -1.16 |
| Low | -1.83 | -1.82 | -1.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.